The immune cell atlas of human neuroblastoma.
cancer
human
immune cell landscape
immuno-oncology
immunotherapy
neuroblastoma
pediatric cancer
prognosis
single-cell RNA sequencing
survival
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 06 2022
21 06 2022
Historique:
received:
07
11
2021
revised:
26
01
2022
accepted:
17
05
2022
pubmed:
11
6
2022
medline:
25
6
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
Understanding the complete immune cell composition of human neuroblastoma (NB) is crucial for the development of immunotherapeutics. Here, we perform single-cell RNA sequencing (scRNA-seq) on 19 human NB samples coupled with multiplex immunohistochemistry, survival analysis, and comparison with normal fetal adrenal gland data. We provide a comprehensive immune cell landscape and characterize cell-state changes from normal tissue to NB. Our analysis reveals 27 immune cell subtypes, including distinct subpopulations of myeloid, NK, B, and T cells. Several different cell types demonstrate a survival benefit. In contrast to adult cancers and previous NB studies, we show an increase in inflammatory monocyte cell state when contrasting normal and tumor tissue, while no differences in cytotoxicity and exhaustion score for T cells, nor in Treg activity, are observed. Our receptor-ligand interaction analysis reveals a highly complex interactive network of the NB microenvironment from which we highlight several interactions that we suggest for future therapeutic studies.
Identifiants
pubmed: 35688160
pii: S2666-3791(22)00189-6
doi: 10.1016/j.xcrm.2022.100657
pmc: PMC9245004
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100657Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL131768
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.V.K. serves on the Scientific Advisory Board to Celsius Therapeutics and Biomage and also consults for Altos Labs.
Références
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Front Immunol. 2017 Nov 03;8:1473
pubmed: 29163537
J Immunol. 2016 May 1;196(9):3581-94
pubmed: 26983787
Cancers (Basel). 2021 Oct 21;13(21):
pubmed: 34771457
Front Immunol. 2020 Sep 02;11:1947
pubmed: 32983125
Blood. 2012 Apr 19;119(16):3734-43
pubmed: 22383801
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34330764
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32603407
Nat Commun. 2019 Sep 2;10(1):3931
pubmed: 31477722
Nat Commun. 2021 Sep 7;12(1):5309
pubmed: 34493726
Clin Cancer Res. 2018 Nov 15;24(22):5673-5684
pubmed: 29784674
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
Leukemia. 2016 Dec;30(12):2283-2292
pubmed: 27499139
Nat Immunol. 2016 Apr;17(4):451-60
pubmed: 26878113
Clin Cancer Res. 2017 Aug 1;23(15):4462-4472
pubmed: 28270499
Nat Genet. 2021 May;53(5):683-693
pubmed: 33767450
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cell Death Dis. 2017 Jun 1;8(6):e2836
pubmed: 28569770
Cell Mol Immunol. 2015 Sep;12(5):558-65
pubmed: 25683611
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cell Immunol. 2018 Aug;330:188-201
pubmed: 29482836
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
Nat Commun. 2020 Oct 8;11(1):5084
pubmed: 33033253
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Immunology. 2020 Jul;160(3):233-247
pubmed: 32031242
PLoS One. 2019 Aug 9;14(8):e0216373
pubmed: 31398192
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Nat Commun. 2019 Oct 17;10(1):4706
pubmed: 31624246
Pediatr Surg Int. 2018 Feb;34(2):195-201
pubmed: 29018959
Front Immunol. 2012 Jan 12;2:98
pubmed: 22566887
Nat Commun. 2020 Nov 25;11(1):5992
pubmed: 33239635
Cancer Cell. 2021 Nov 8;39(11):1464-1478.e8
pubmed: 34719426
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Nat Methods. 2019 Aug;16(8):695-698
pubmed: 31308548
Oncoimmunology. 2013 Mar 1;2(3):e23618
pubmed: 23802089
Cancer Immunol Immunother. 1996 Mar;42(3):170-8
pubmed: 8640845
Stem Cell Res. 2015 Sep;15(2):419-26
pubmed: 26342562
Clin Immunol. 2020 Feb;211:108343
pubmed: 31931123
PeerJ. 2019 Dec 10;7:e8017
pubmed: 31844563
Front Mol Neurosci. 2019 Jan 29;12:9
pubmed: 30760980
Nat Rev Immunol. 2021 Apr;21(4):209-220
pubmed: 33024284
Cancer Res. 1996 Jan 15;56(2):362-9
pubmed: 8542593
Nat Commun. 2019 Apr 4;10(1):1530
pubmed: 30948783
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Front Immunol. 2020 Feb 13;11:167
pubmed: 32117298
Nat Genet. 2021 May;53(5):694-706
pubmed: 33833454
Carcinogenesis. 2013 May;34(5):1081-8
pubmed: 23349014
J Pathol. 2016 Oct;240(2):211-23
pubmed: 27425378
J Leukoc Biol. 2019 Aug;106(2):309-322
pubmed: 30776148
Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):
pubmed: 33500353
Clin Cancer Res. 2021 Apr 15;27(8):2179-2189
pubmed: 33504555
Einstein (Sao Paulo). 2015 Jul-Sep;13(3):469-73
pubmed: 26466066
Front Immunol. 2019 Feb 08;10:173
pubmed: 30800127
Signal Transduct Target Ther. 2020 Oct 9;5(1):233
pubmed: 33037186
J Clin Oncol. 2012 Oct 1;30(28):3525-32
pubmed: 22927533
Arthritis Res Ther. 2013;15 Suppl 1:S3
pubmed: 23566754
PLoS One. 2017 Aug 1;12(8):e0181868
pubmed: 28763457
Front Immunol. 2020 Jan 21;10:3038
pubmed: 32038612
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Cancer Cell. 2021 May 10;39(5):662-677.e6
pubmed: 33861994
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cell. 2021 Mar 4;184(5):1281-1298.e26
pubmed: 33592174
Nat Rev Immunol. 2006 Apr;6(4):295-307
pubmed: 16557261
Sci Immunol. 2021 Feb 12;6(56):
pubmed: 33579751
Adv Cancer Res. 2003;90:127-56
pubmed: 14710949
Cancers (Basel). 2021 Apr 06;13(7):
pubmed: 33917501
Sci Immunol. 2019 Apr 5;4(34):
pubmed: 30952804
Clin Cancer Res. 2016 Aug 1;22(15):3849-59
pubmed: 26957560
Nat Neurosci. 2021 Apr;24(4):595-610
pubmed: 33782623
Cancers (Basel). 2021 Apr 26;13(9):
pubmed: 33926057
Cell. 2020 Aug 20;182(4):886-900.e17
pubmed: 32783918
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
J Transl Med. 2018 Jul 17;16(1):198
pubmed: 30016977
Oncoimmunology. 2015 Apr 2;4(9):e1019981
pubmed: 26405592
Cancer Cell. 2020 Nov 9;38(5):716-733.e6
pubmed: 32946775
Sci Adv. 2021 Feb 5;7(6):
pubmed: 33547074
Semin Cancer Biol. 2004 Oct;14(5):365-73
pubmed: 15288262
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Nat Protoc. 2020 Apr;15(4):1484-1506
pubmed: 32103204
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169
pubmed: 30897608
Eur J Cancer. 2021 Feb;144:123-150
pubmed: 33341446
Nature. 2021 Nov;599(7885):477-484
pubmed: 34732890
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Arthritis Res Ther. 2018 Jan 25;20(1):9
pubmed: 29370826